Prostate Cancer P D:健康和前列腺癌不同阶段男性的身体成分、身体功能和生活质量

2021-02-09 AlexYang MedSci原创

最近,有研究人员比较了PC和非癌症对照组(CON)各进展阶段组患者的身体成分、身体功能和QoL情况。

最近,有研究人员比较了PC和非癌症对照组(CON)各进展阶段组患者的身体成分、身体功能和QoL情况

研究人员在对激素敏感的PC(HSPC,n=43)或转移性去势抵抗性PC(mCRPC,n=22)或CON(n=37)的男性中,测定了相对和绝对瘦肉和脂肪质量、身体功能(6米步行、椅子站立、定时起身走[TUG]以及爬楼梯)和QoL。结果表明,相对的身体成分在所有分组中存在差异。mCRPC与CON的绝对脂肪质量相比少了39%。与CON和HSPC相比,mCRPC的TUG和椅子站立分别慢了约71%和约33%,而mCRPC与CON相比,爬楼梯慢了约29%,6米步行慢了约18%。相对身体成分与身体功能相关(r=0.259-0.385)。虽然身体成分和身体功能不影响QoL,但mCRPC的总体QoL和几个子量表与CON存在临床相关差异。

身体组成、身体功能和生活质量之间的相关性

最后,研究人员指出,PC进展与身体成分和身体功能的恶化有关。由于组间ADT长度相似,mCRPC的ARSI使用可能部分促成了这些变化。鉴于ADT期间改善瘦肉质量的困难,减少脂肪的干预措施可能会减轻激素治疗的副作用。

原始出处:

Erik D Hanson, Cameron K Stopforth, Mohamdod Alzer et al. Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. Prostate Cancer P D. Jan 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791646, encodeId=13131e91646b6, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Sep 28 08:15:55 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364693, encodeId=82101364693a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537418, encodeId=0993153e418c6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602338, encodeId=c5561602338d9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040953, encodeId=3ef3104095375, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Feb 09 13:15:55 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791646, encodeId=13131e91646b6, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Sep 28 08:15:55 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364693, encodeId=82101364693a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537418, encodeId=0993153e418c6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602338, encodeId=c5561602338d9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040953, encodeId=3ef3104095375, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Feb 09 13:15:55 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-11 lsndxfj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791646, encodeId=13131e91646b6, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Sep 28 08:15:55 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364693, encodeId=82101364693a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537418, encodeId=0993153e418c6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602338, encodeId=c5561602338d9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040953, encodeId=3ef3104095375, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Feb 09 13:15:55 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791646, encodeId=13131e91646b6, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Sep 28 08:15:55 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364693, encodeId=82101364693a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537418, encodeId=0993153e418c6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602338, encodeId=c5561602338d9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040953, encodeId=3ef3104095375, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Feb 09 13:15:55 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-11 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1791646, encodeId=13131e91646b6, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Tue Sep 28 08:15:55 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364693, encodeId=82101364693a5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537418, encodeId=0993153e418c6, content=<a href='/topic/show?id=b1f09320892' target=_blank style='color:#2F92EE;'>#身体成分#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93208, encryptionId=b1f09320892, topicName=身体成分)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2ac12863902, createdName=chengjn, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602338, encodeId=c5561602338d9, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Feb 11 01:15:55 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040953, encodeId=3ef3104095375, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Feb 09 13:15:55 CST 2021, time=2021-02-09, status=1, ipAttribution=)]
    2021-02-09 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

J Clin Oncol:高风险和极高风险前列腺癌中仅前列腺与全盆腔放射治疗的比较

最近,有研究人员报告了一项比较高风险前列腺癌中预防性全盆腔结节放疗与单纯前列腺放疗(PORT)的随机试验临床结果。

JAMA Netw Open:恩扎鲁胺与比卡鲁胺联合雄激素阻断疗法对转移激素敏感型前列腺癌男性的临床疗效

最近,有研究人员比较了恩杂鲁胺与比卡鲁胺联合使用ADT对男性mHSPC的疗效,并对黑人患者进行了亚组分析。

Int J Nanomedicine:外泌体通过上调血红素加氧酶-1促进雄激素依赖性前列腺癌细胞向不依赖雄激素转变

去势抵抗性前列腺癌(CRPC)仍不能治愈,尽管CRPC的机制已有广泛研究。研究表明,肿瘤微环境中的外泌体有利于前列腺癌的发展和进展。然而,外泌体在CRPC进展过程中的作用尚未确定。

Prostate Cancer P D:非转移性前列腺癌中局部治疗与根治性前列腺切除术的比较:倾向性评分匹配研究

局部治疗(FT)切除的是前列腺癌的部分区域,而不是整个腺体。最近,有研究人员比较了FT与根治性前列腺切除术(RP)的肿瘤学结果。

Eur Radiol:对于低风险局灶性前列腺癌,MRI上哪些征象提示肿瘤进展呢?

有些前列腺癌病灶处在进展低风险时,直接做手术有点不值当的,不做手术吧又有点不放心!那对于这样的前列腺癌,我们该拿它如何是好呢?

Clin Cancer Res:PSMA靶向AMG160疗法在转移去势抵抗性前列腺癌临床前模型中具有强效的抗肿瘤活性

转移去势抵抗性前列腺癌(mCRPC)仍然是一种远未满足医疗需求的疾病,因为大多数患者在现有的治疗方法中不能获得持续的响应。前列腺特异性膜抗原(PSMA)是mCRPC的一个引人注目的靶标,其在原发性和转